Skip to main content
Premium Trial:

Request an Annual Quote

PlexBio Inks Italian Distribution Deals

NEW YORK (360Dx) – Taiwanese firm PlexBio today announced distribution deals for its products in Italy.

PlexBio and Eurclone Diagnostica inked an exclusive distribution contract to market and sell PlexBio's IntelliPlex 1000 πCode Processor, the PlexBio 100 Fluorescent Analyzer, and several PlexBio CE-marked IVD kits for molecular diagnostics in a targeted segment of the Italian IVD clinical market, PlexBio said.

The PlexBio 100 Fluorescent Analyzer received CE marking in August.

Separately, Euroclone, the parent firm of Euroclone Diagnostica, will be the exclusive distributor of the  IntelliPlex 1000 πCode Processor and the PlexBio 100 Fluorescent Analyzer for the Italian life science research market. The deal also provides for the sale by Euroclone of research reagents based on PlexBio's πCode MicroDisc technology and accessories.

Financial and other terms of the agreements were not disclosed.

The deals provide PlexBio a direct sales and support channel in Italy, the firm said.

"Establishing these distribution relations with Euroclone is a critical first step to PlexBio's European market entry strategy and we are very happy that, together with our partners at Euroclone, we will be able to provide an innovative and powerful workflow solution for two key multiplex testing market segments in Italy," PlexBio COO Stuart Palmer said in a statement.

Earlier this year, PlexBio announced an expansion of its collaboration with Denka to include the codevelopment of a molecular diagnostic platform for infectious disease testing.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more